Non-Compliance by Indian Drug Manufacturer: Cross Contamination

Recommendation
16-18 September 2025
Barcelona, Spain
Organisation of a GMP-compliant Site Change
So-called Non-Compliance reports are summaries of inspections conducted by European inspectors. They are publicly available on the EMA’s (European Medicines Agency) website. In the present case, the Non-Compliance Report is based on the inspection of an Indian pharmaceutical manufacturer in Bangalore, which was conducted by the MHRA in November 2017.
The report concerns the manufacturing of non-sterile dosage forms: tablets and capsules as well as their primary and secondary packaging. The inspectors found the cleaning procedure and the proof of cleaning success during product changes to be inadequate. As a result of the inspection, the GMP certificate was withdrawn. Due to the severity of the deficiencies found and the resulting cross contamination risk, the MHRA recommends a precautionary recall of all affected batches in the market.
Source: EudraGMDP Database
Related GMP News
09.07.2025The USP has revised the General Chapter <1231> on Pharmaceutical Water
25.06.2025Deficiencies in the Water System: Warning Letter to US Manufacturers of OTC Products
11.06.2025Warning Letter to Chinese Manufacturer due to serious Sterility and Hygiene Deficiencies
04.06.2025FAQs regarding Cross Contamination
04.06.2025GMP Deficiencies at French Sterile Manufacturer
14.05.2025Process Validation and Pharmaceutical Water Deficiencies at a US Manufacturer